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P soriasis is a common chronic inflammatory skin disorder that is characterized by scaly,  erythema-
tous,  sharply demarcated plaques in different sizes and 
shapes [1].  Abnormal epidermal proliferation and cel-
lular infiltration including T-cells and neutrophils are 
histologically observed in the skin lesions [1].  The 
numbers of Th1 and Th17 cells are particularly elevated 
in psoriatic patients,  and these cells are thought to play 
critical roles in the pathogenesis [1 , 2].  Some patients 
with psoriasis will develop psoriatic arthritis,  which is 
characterized by diverse clinical features including dac-
tylitis,  enthesitis,  nail pitting,  onycholysis,  and axial 
involvement [3].  
The treatment for psoriasis has dramatically changed 
over the last 10 years with the introduction of biologics.  
While biologics including anti-TNF-α,  anti-IL12/IL-23,  
anti-IL-17A,  and anti-IL-17RA antibodies are all quite 
effective,  they are known to exert immunosuppressive 
effects that might increase the risk of infectious diseases 
or malignancies.  Few reports have examined the risk of 
cancer induced by biologics for psoriasis,  since these 
agents have such a short history of use.
Case Report
A 74-year-old woman was treated at our hospital for 
psoriasis vulgaris and psoriatic arthritis complicated by 
breast cancer.  She had first developed eruptions and 
received a diagnosis of psoriasis when she was 17 years 
old.  Decades later,  at the age of 55 years,  she devel-
oped joint pain and was diagnosed with psoriatic 
arthritis.  She underwent several systemic treatments:  
etretinate (details unknown),  adalimumab at 40-80 mg 
every 2 weeks for 1 year,  ustekinumab at 45 mg every 
3 months for 7 months,  cyclosporine at 150-200 mg/day 
for 9 months,  and methotrexate at 6-12 mg/week for 
5 months.  Breast tumor was identified at 72 years of age,  
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when she was receiving methotrexate at 8 mg/week.  
Contrast-enhanced T1-weighted fat-saturated magnetic 
resonance imaging showed regions of clumped,  non-
mass-like enhancements in all four quadrants of the 
right breast (Fig. 1A).  Cytology of a specimen from fine 
needle aspiration biopsy showed class V results,  and 
breast cancer was diagnosed.  Methotrexate was discon-
tinued and the patient underwent dissection and senti-
nel lymph node biopsy,  which yielded negative results 
(T3N0M0,  stage IIb).  The histological type was muci-
nous carcinoma (Fig. 1B).  The patient has since been 
receiving hormone therapy of anastrozole at 90 mg/day,  
and no recurrence has been seen.  However,  her psori-
atic skin lesions gradually worsened with an elevated 
Psoriasis Area and Severity Index (PASI) of 14.0 
(Fig. 2A , B).  We therefore decided to re-introduce 
methotrexate at day 90 after its discontinuation,  and her 
PASI promptly decreased to 2.0.  No joint symptoms 
were observed.  No recurrence of breast cancer has been 
seen as of the time of writing,  2 years after re-introduc-
ing methotrexate.
Discussion
Psoriasis patients are thought to have an increased 
risk of some cancers,  especially lymphoma,  and long-
term psoriasis and more severe disease might increase 
the risk [4].  There are very few case reports of patients 
with psoriasis and breast cancer [5-7],  and the associa-
tion of psoriasis with the incidence of breast cancer had 
been controversial [4 , 8-11].  However,  Chiesa Fuxench 
et al. performed a large-scale cohort study (198,366 pso-
riasis and 937,716 control group patients) and showed 
that there was no association of psoriasis with cancer of 
the breast,  colon,  prostate,  or leukemia,  although sig-
nificant associations between psoriasis and each of non-
melanoma skin cancer,  lymphoma,  and lung cancer 
were identified [12].  In our patient,  the breast cancer 
was diagnosed after systemic treatments for psoriasis 
including etretinate,  cyclosporine,  methotrexate,  
adalimumab,  and ustekinumab.  Therefore,  we consid-
ered the possibility that these systemic treatments could 
have triggered breast cancer in our patient.
Etretinate is a synthetic retinoid in common use in 
Japan.  In general,  retinoid is thought to have antican-
cer activity and fewer immunosuppressive effects.  
Retinoid therapy alone has not been reported to be 
associated with a risk of malignancy [13].  Cyclosporine 
is a calcineurin inhibitor originally used as an immuno-
suppressive agent for organ transplantation and is well-
known to increase the risk of malignancy [14].  In par-
ticular,  psoriatic patients treated with cyclosporine have 
been reported to show an increased risk of non-mela-
noma skin cancers [15].  Methotrexate is a classical 
antifolate and was originally developed as an anti-can-
cer agent.  In addition,  low-dose methotrexate has been 
widely used as an immunosuppressive agent for inflam-
matory diseases such as rheumatoid arthritis.  The asso-
ciation between methotrexate and risk of malignancy 
has not been considered significant [16].  Adalimumab 
is a humanized anti-TNF-α monoclonal antibody that 
has been in clinical use for around a decade.  Very 
recently,  an increased incidence of cutaneous squamous 
cell carcinomas among patients with psoriasis treated 
using TNF-α inhibitors has been reported [17].  
Ustekinumab is a humanized anti-IL-12/23p40 mono-
clonal antibody that has been in clinical use since 2010,  
and has not been reported as associated with any 
increased risk of malignancy [18].  Although neither of 
these biologics has been associated with an increased 
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Fig.  1　 Findings of breast cancer.    
A,  Contrast-enhanced T1-weighted fat-saturated image of the right 
breast; B,  Pathological ﬁnding of breast cancer (200×,  hematox-
ylin and eosin stain).
A B
Fig.  2　 Findings of psoriatic plaques at recurrence.    
A,  Psoriatic plaques on the abdomen; B,  Psoriatic plaques on the 
lower extremities.   
risk of breast cancer so far,  our patient did receive both 
of them,  which might have affected her anti-cancer 
immunity.  Alternatively,  the combined use of 
immune-suppressive agents and biologics might have 
affected the anti-cancer immunity,  although the dura-
tion of each treatment was short.  Further accumulation 
of cases followed over the long term will be needed to 
estimate the effects of the various biologics for psoriasis 
on the risk of malignancy.
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